To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05909397
Title A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer (VERITAC-3)
Acronym VERITAC-3
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Pfizer
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | SVK | ITA | HUN | ESP | CHE | BRA | AUS


No variant requirements are available.